1428
272
130
86
83
82
78
64
54
51
49
47
43
40
39
37
35
32
30
29
28
27
27
26
25
24
24
20
17
17
16
15
15
15
14
14
13
13
12
12
12
12
12
11
11
10
10
9
8
8
8
8
8
8
7
6
6
6
6
6
6
6
6
6
5
5
5
5
5
5
5
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
10189
1018
2789
278
2989
298
J CLIN ONCOL
RAINBOW-Asia: A randomized, multicenter, double-blind, phase III study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line chemotherapy with platinum and fluoropyrimidine
PDF的下载单位、IP信息已删除
(2025-6-4)